Seeking Alpha

Perrigo (PRGO +0.2%) announces that it nabbed final FDA approval for Desloratadine. The product...

Perrigo (PRGO +0.2%) announces that it nabbed final FDA approval for Desloratadine. The product - set for commercial launch in July 2012 - is a generic version of Schering-Plough's Clarinex allergy relief treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs